Also known as: BI 456906
A GLP-1 and glucagon dual agonist being developed for obesity and fatty liver (MASH).
Educational reference, not medical advice. Many compounds here are not approved, and products sold as research chemicals are not checked for purity. Plan any use with a licensed clinician.
How it works
Reduces appetite and increases liver fat burning.
Evidence by goal
| Goal | Grade | What the grade means |
|---|---|---|
| Blood sugar & metabolic | B | Human trials (smaller, mixed, or approved outside the US) |
| Fat loss & weight | B | Human trials (smaller, mixed, or approved outside the US) |
At a glance
- Route
- Subcutaneous weekly
- Half-life
- About 1 week
Reported dosing
Phase 3 dose-finding; not established.
Timing: Same day each week.
Cycle: Trial-defined.
From approved labels where they exist, otherwise from published trials and practitioner reports.
Side effects
- GI effects
- Raised heart rate
Who should avoid it
- Not available outside trials
Often combined with
None.
Key findings
Phase 2 showed strong liver-fat and MASH improvements.
Where it is legal (Oct 2026)
| US | Not approved |
|---|---|
| Canada | Not approved |
| Mexico | Not approved |
| EU | Not approved |
Sources
Open Survodutide in the Peptide Guide Compare all peptides by goal
Last reviewed November 2026. Regulatory status reflects the US unless noted and changes often.